Metreleptin, being a leptin analogue administered once-daily subcutaneously, is used in the treatment of obesity in patients with congenital leptin deficiency or congenital/acquired lipodystrophy. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.